June 27, 2022


Its all about the Health

PARP Inhibitors for the Treatment of Ovarian Cancer – Gottfried Konecny, MD

1 min read

Join UCLA oncologist Gottfried Konecny, MD, for an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat

All Rights Reserved © ACN 2020

ACN Privacy Policies
Area Control Network (ACN)
Area Control Network
Area Control Network Center